Despite the drugs cardiovascular benefits, both trials found no significant difference in retinopathy outcomes between the GLP-1RAs and placebo groups
As noted, however, the peptide has exhibited minor to no side effects when administered to both animal subjects and humans, across a variety of research settings and dosages
Last reviewed: June 24, 2026 Last updated: June 24, 2026 Written by: Jay Hastings, CEO of PlexusDx Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations
Patients undergoing surgery required fewer diabetes, hypertension, cholesterol, and kidney disease medicines in the long term
K.WilliamsD
Constipation management guidelines